Clinical Trials Directory

Trials / Completed

CompletedNCT03149445

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

A Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Multi-Center Safety and Efficacy Study of Co-Administration of Tesofensine/Metoprolol for 12 Weeks in Adult and Adolescent Patients With Prader-Willi Syndrome (PWS), Followed by Two Open Label 12 Weeks Extension Periods for Adolescent Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Saniona · Industry
Sex
All
Age
12 Years – 30 Years
Healthy volunteers
Not accepted

Summary

Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study followed by two open label extension periods.

Detailed description

Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study. Study medication will be administered for 91 days. The study will be conducted in two steps: * Step 1 - 9 adult subjects with PWS was treated. * Sponsor review - following the completion of the treatment of the adult subjects, unblinded efficacy, safety, Pharmacokinetic (PK) data as well as all data from the study in subjects with type 2 diabetes (TM001) will be reviewed by sponsor and an interim analysis will be done. Following competent authority positive opinion regarding the interim analysis and unblinded data the study will proceed to: * Step 2 - 9 adolescent subjects with PWS was treated. * OLE (Open Label Extension) I - Participation in a 12-week OLE I was offered to subjects who completed Step 2. 8 subjects entered OLE I. * OLE (Open Label Extension) II - Participation in a 12-week OLE II was offered to subjects who completed OLE I. 6 subjects continued to OLE II.

Conditions

Interventions

TypeNameDescription
DRUGTesofensine/MetoprololStudy medication will be administered for 91 days.
DRUGPlacebosStudy medication will be administered for 91 days.

Timeline

Start date
2017-03-30
Primary completion
2019-07-22
Completion
2019-07-22
First posted
2017-05-11
Last updated
2024-02-26
Results posted
2024-02-26

Locations

2 sites across 2 countries: Czechia, Hungary

Source: ClinicalTrials.gov record NCT03149445. Inclusion in this directory is not an endorsement.